Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
6.795
+1.275 (+23.10%)
Streaming Delayed Price
Updated: 10:07 AM EST, Jan 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
IBRX Stock Extends Rally On FDA Feedback For ANKTIVA Bladder Cancer Filing
↗
Today 7:13 EST
Via
Stocktwits
Nasdaq, S&P 500 Futures Slide As Trump Ramps Up Greenland Threats: Why NFLX, CRML, TSLA, VERO, SRXH Are On Traders' Radar Today
↗
Today 3:31 EST
Retail sentiment on Stocktwits has flipped bearish on SPY and QQQ amid elevated message volumes and rising volatility.
Via
Stocktwits
Topics
Artificial Intelligence
ETFs
Economy
Why Is ImmunityBio Stock Back In Retail Spotlight Today?
↗
January 19, 2026
The company outlined progress across multiple cancer programs following last week's series of clinical and regulatory updates.
Via
Stocktwits
Nasdaq, S&P 500 Futures Slide On Greenland Tensions: Why NVDA, MU, IBRX, CRML And VERO Are On Traders’ Radar Today
↗
January 19, 2026
Via
Stocktwits
Topics
Stocks
Why IBRX Stock Is One Of The Biggest Pre-Market Movers Today
↗
January 16, 2026
Via
Stocktwits
IBRX Stock Continues Rally — What’s Driving The Optimism Today?
↗
January 15, 2026
Via
Stocktwits
IBRX Stock Finds Retail Cheer After Company’s Immunotherapy For Bladder Cancer Gets Saudi FDA Approval
↗
January 14, 2026
Via
Stocktwits
IBRX Garners Retail Attention On Positive Update In Immunotherapy For Lung Cancer Patients
↗
January 13, 2026
Via
Stocktwits
Stock Market Today, Jan. 16: ImmunityBio Soars After Anktiva Revenue Jumps 700 Percent Year Over Year
↗
January 16, 2026
Explosive Anktiva sales, new cancer data, and fresh approvals are rapidly redefining this immunotherapy story, today, Jan. 16, 2026.
Via
The Motley Fool
Topics
Stocks
Which stocks are experiencing notable movement on Friday?
↗
January 16, 2026
Via
Chartmill
Why ImmunityBio Stock Is Skyrocketing Again Today
↗
January 16, 2026
It has been an incredible week of positive news for ImmunityBio.
Via
The Motley Fool
Curious about the most active stocks on Friday?
↗
January 16, 2026
Via
Chartmill
ImmunityBio Stock Breaks Out Of Long Slump, Tests $3 Zone: Ex-UBS Analyst Flags ‘Huge’ Bullish Signals
↗
September 17, 2025
Via
Stocktwits
Keep an eye on the top gainers and losers in Friday's session.
↗
January 16, 2026
Via
Chartmill
Friday's session: gap up and gap down stocks
↗
January 16, 2026
Via
Chartmill
Stock Market Today, Jan. 15: ImmunityBio Surges After Anktiva Revenue Jumps 700%
↗
January 15, 2026
On Jan. 15, 2026, investors took note of Anktiva's explosive sales ramp, its geographic expansion potential, and a possible new indication.
Via
The Motley Fool
Topics
Earnings
Stocks
Thursday's session: top gainers and losers
↗
January 15, 2026
Via
Chartmill
Which stocks are moving on Thursday?
↗
January 15, 2026
Via
Chartmill
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
November 28, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via
Chartmill
A Fresh $16 Million Bet on ImmunityBio: What Investors Should Know
↗
November 19, 2025
A major fund just opened a multimillion-dollar position in ImmunityBio—and the move could hint at rising confidence in this clinical-stage immunotherapy pipeline.
Via
The Motley Fool
Heights Capital Walks From Archer Aviation: What It Means for Investors
↗
November 19, 2025
One major investor just walked away from Archer Aviation. Here’s what that move does—and doesn’t—signal for the future of urban air mobility.
Via
The Motley Fool
Heights Capital Just Ditched Its $12.5 Million AMSC Stake. Here’s What That Might Mean.
↗
November 19, 2025
One fund just walked away from American Superconductor—but the company’s role in the future of grid resiliency might be more important than any single quarterly filing suggests.
Via
The Motley Fool
Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks
↗
October 22, 2025
Here's a look at the most heavily shorted stocks in the market as investors look for the next Beyond Meat.
Via
Benzinga
Biotech Breakouts: 3 Stocks With Massive Upside Potential
↗
September 17, 2025
Biotech stocks are highly volatile; however, these biotech stocks have key trial results this fall that could spark sharp moves and long-term growth potential
Via
MarketBeat
Not Just Opendoor & GoPro: JPMorgan Identifies 4 Emerging 'Meme Stocks' Firing Up Social Media And Hedge Fund Shorts
↗
September 12, 2025
Via
Stocktwits
What's Going On With ImmunityBio Shares Tuesday?
↗
August 26, 2025
ImmunityBio shares are trading higher Tuesday after the company announced its chemotherapy-free combination showed 100% disease control results and is planning a Phase 2 trial.
Via
Benzinga
IBRX Sales Soar 2,540%
↗
August 05, 2025
Via
The Motley Fool
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper
↗
July 22, 2025
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.
Via
Benzinga
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
↗
June 02, 2025
Via
Benzinga
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside
↗
May 18, 2025
Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.
Via
Stocktwits
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.